For information on warnings, contraindications, and precautions, please refer to the "Drug information" page in the package insert.

The change (mean ± SD) in the complete spontaneous bowel movement frequency from Week 2 of the observation period to Week 1 of the treatment period was 0.62 ± 1.44 times in the placebo group and 3.39 ± 3.86 times in the GOOFICE^® group. The change in the complete spontaneous bowel movement frequency from Week 2 of the observation period to Week 2 of the treatment period was 0.86 ± 1.45 times in the placebo group and 2.98 ± 3.10 times in the GOOFICE^® group. In the GOOFICE^® group, the change in the complete spontaneous bowel movement frequency significantly increased as compared with the placebo group at both Week 1 and Week 2 of the treatment period (p < 0.0001 at both Week 1 and Week 2 of the treatment period, analysis of covariance).

A comparative test was conducted to examine the changes in the spontaneous bowel movement frequency and the complete spontaneous bowel movement frequency between Week 2 of the observation period and Weeks 4, 12, 24, 36, and 52 of the treatment period. At all time points, significant increases were observed as compared with Week 2 of the observation period (p < 0.0001 for all, one-sample t-test).
The spontaneous bowel movement frequency and the complete spontaneous bowel movement frequency per week increased from Week 1 of the treatment period and remained as follows up to Week 52.